In addition to the tumor cell-autonomous Bcl-2-dependent resistance to Regorafenib, we identified a non-autonomous mechanism dependent on infiltrating macrophages that involves the COX2-PGE2 signaling reducing the susceptibility to regorafenib and promotes further tumor growth. This evidence concerns the gene BCL2 and neoplasm.